Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction

Recruiting Observational Study
Myocardial Infarction (MI) ST-Elevation Myocardial Infarction STEMI STEMI (STE-ACS) Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
300 (estimated)
Sponsor
Medical University of Vienna · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority over thrombolysis, plain balloon angioplasty, and bare-metal stents. Recently, the use of drug-coated balloons (DCB) has expanded dramatically across a variety of anatomi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * All ST-elevation MI undergoing Primary PCI Exclusion Criteria: * In-stent culprit lesion * Contraindications to antiplatelets * Stent implantation within 3 months before enrollment * Cardiac arrest, intubation, or cardiogenic shock * Life-expectancy less than one year
Contacts

Riccardo Terzi, MD, BSc

+393312127467

riccardo.terzi1@gmail.com

CONTACT